Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 2.50 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 71 |
MAHWAH, N.J., May 14, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, is pleased to announce the signing of a Phase III clinical supply agreement for a novel enzyme replacement therapy to treat a rare endocrinological disease.
Key Insights KORU Medical Systems to hold its Annual General Meeting on 9th of May Salary of US$563.1k is part of CEO...
Discover how KORU Medical Systems achieved its highest quarterly revenue and is strategically positioning for future growth.